Acyclovir Reaches Clinical Trial
Authors: A. MARTIN LERNER
Journal: Annals of Internal Medicine (1982)

Editorials1 March 1982Acyclovir Reaches Clinical TrialA. MARTIN LERNER, M.D.A. MARTIN LERNER, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-96-3-370 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe report in this issue by Wade and colleagues (1), from the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle, and the Burroughs Wellcome Co. , describes patients who developed mucocutaneous herpes simplex virus infections after bone marrow transplantation and were successfully treated with acyclovir (acycloguanosine; 9-(2-hydroxyethoxymethyl) guanine; zovirax, acyclovir). A second paper, by Strauss and colleagues (2), from the National Institute of Allergy and Infectious Diseases in Bethesda and the Burroughs Wellcome Co., records a similar accomplishment along with proplylaxis of recurrent mucocutaneous herpes simplex virus infections in five severely immunocompromised patients with nucleoside phosphroylase...References1. WADENEWTONMCLARENFLOURNOYKEENEYMEYERS JBCNRJ. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infectious after marrow transplantations: a double-blind trial. Ann Intern Med. 1982;96:265-9. LinkGoogle Scholar2. STRAUSSMITHBRICKMANDE MIRANDAMCLARENKEENEY SHCPCR. Acyclovir for chronic mucocutaneous herpes simplex virus infection in immunosuppressed patients. Ann Intern Med. 1982;96:270-7. LinkGoogle Scholar3. SARELBURNSLASKINSANTOSLIETMAN RWOGP. Acyclovir prophylaxis of herpes simplex virus infections: a randomized double-blind, controlled trial in bone marrow transplant recipients. N Engl J Med. 1981;305:63-7. CrossrefMedlineGoogle Scholar4. CHOUGALLAGHERMERIGAN SJT. Controlled clinical trial of intravenous acyclovir in heart transplant patients with mucocutaneous herpes simplex infections. Lancet. 1981;2:1392-4. CrossrefGoogle Scholar5. SELBYPOWLESJAMESON PRB. Parenteral acyclovir therapy for herpesvirus infections of man. Lancet. 1979;2:1267-70. CrossrefMedlineGoogle Scholar6. CUPPSSTRAUSWALDMANN TST. Successful treatment with acyclovir of an immunodeficient patient infected simultaneously with multiple herpesviruses. Am J Med. 1981;70:882-6. CrossrefMedlineGoogle Scholar7. MITCHELLGENTRYBOENBEANGROUTHBALFOUR CSJBKH. Acyclovir therapy for mucocutaneous herpes simplex infections in immune compromised patients. Lancet. 1981;2:1389-92. CrossrefMedlineGoogle Scholar8. CH'IENCANNONCHARAMELLA LNL. Effect of adenine arabinoside on severe Herpesvirus hominis infections in man. J Infect Dis. 1973;128:658-63. CrossrefMedlineGoogle Scholar9. CHAMPNEYLAUTERBAILEYLERNER KCEA. Antiherpes-virus activity in human sera and urines after administration of adenine arabinoside: in vitro and in vivo synergy of adenine arabinoside and arabinosylhypoxanthine in combination. J Clin Invest. 1978;62:1142-53. CrossrefMedlineGoogle Scholar10. GOTTLIEBBODEY JG. Possible bone-marrow depression by ara-A therapy for disseminated herpes zoster. N Engl J Med. 1974;290:914. Letter. CrossrefMedlineGoogle Scholar11. ELIONFURMANFYFEDE MIRANDABEAUCHAMPSCHAEFFER GPJPLH. Selectivity of action of an anti-herpetic agent, 9-(2-hydroxymethyl) guanine. Proc Nat Acad Sci USA. 1977;74:5716-20. CrossrefMedlineGoogle Scholar12. DE MIRANDAWHITLEYBLUM PRM. Acyclovir kinetics after intravenous infusion. Clin Pharm Ther. 1979;26:718-28. CrossrefMedlineGoogle Scholar13. TENSERMILLERRAPP RRF. Trigeminal ganglion infection by thymidine kinase-negative mutants of herpes simplex virus. Science. 1979;205:915-7. CrossrefMedlineGoogle Scholar14. ST. CLAIRFURMANLUBBERSELION MPCG. Inhibition of cellular α and virally induced deoxyribonucleic acid polymerases by the triphosphate of acyclovir. Antimicrob Agents Chemother. 1980;18:741-5. CrossrefMedlineGoogle Scholar15. KRASNYDE MIRANDABLUMELION HPRG. Pharmacokinetics and bioavailability of acyclovir in the dog. J Pharm Exper Ther. 1981;215:281-8. Google Scholar16. CRUMPACKERSCHNIPPERZAIALEVIN CLJM. Growth inhibition by acycloguanosine of herpes viruses isolated from human infections. Antimicrob Agents Chemother. 1979;15:642-5. CrossrefMedlineGoogle Scholar17. COLBYSHAWELIONPAGANO BJGJ. Effects of acyclovir [9-(2-hydroxyethoxy methyl) guanine] on Epstein-Barr virus DNA replication. J Virol. 1980;34:560-8. CrossrefMedlineGoogle Scholar18. JORDANFRIEDMERIGAN GRT. Administration of human leukocyte interferon in herpes zoster: I. Safety, circulating antiviral activity, and host responses to infection. J Infect Dis. 1974;130:56-62. CrossrefMedlineGoogle Scholar19. DECLERQ E. Therapeutic potentials of BVDU [E-5-(2-bromovinyl)-2'-deoxyuridine] as an anti-herpes drug. Chemoterapia Antimicrobica. 1981;4:70-5. Google Scholar20. HELGSTRANDFLODHLERNESTEDTLUNDSTRÖMOBERG EHJJB. Trisodium phosphoformate: antiviral activities, safety evaluation and preliminary clinical results. In: COLLIER LH, OXFORD J, eds. Developments in Antiviral Therapy. New York: Academic Press; 1980:63-83. Google Scholar21. LEVINLEARY MP. Inhibition of human herpesviruses by combination of acyclovir and human leukocyte interferon. Infect Immunol. 1981;32:995-9. CrossrefMedlineGoogle Scholar22. GEPHARTLERNER JA. Comparison of the effects of arabinosyladenine, arabinosylhypoxanthine, and arabinosyl adenine 5'-monophosphate against herpes simplex virus, varicella-zoster virus, and cytomegalovirus with their effects on cellular deoxyribonucleic acid synthesis. Antimicrob Agents Chemother. 1981;19:170-8. CrossrefMedlineGoogle Scholar23. BRYSONCONNORSWEETMANCAREYSTUCKEYBUCHANAN YJLSMR. Determination of plaque inhibitory activity of adenine arabinoside (9-β-D-arabinofuranosyladenine) for herpesviruses using an adenosine deaminase inhibitor. Antimicrob Agents Chemother. 1974;6:98-101. CrossrefMedlineGoogle Scholar24. LERNERRAHIMIBAILEY AME. Antiviral drugs in combination: I. Simultaneous in vitro tests of several antiviral agents in seven tissue cultures with the use of computer methods to calculate apparent hinge-points and draw isobolograms. Clin Res. 1981. In press. Google Scholar25. FINTER N. Dye uptake methods for assessing viral cytopathogenicity and their application to interferon assays. J Gen Virol. 1969;5:419-27. CrossrefGoogle Scholar26. WHITLEY R. Diagnosis and treatment of herpes simplex encephalitis. Ann Rev Med. 1981;32:335-40. CrossrefMedlineGoogle Scholar27. LAUTERBAILEYLERNER CEA. Microbiological assays and neurological toxicity during use of adenine arabinoside in humans. J Infect Dis. 1976;134:75-9. CrossrefMedlineGoogle Scholar28. FIELDDARBYWILDY HGP. Isolation and characterization of acyclovir-resistant mutants of herpes simplex virus. J Gen Virol. 1980;49:115-24. CrossrefMedlineGoogle Scholar29. SMITHKENNELLPOIRERLYND KWRF. In vitro and in vivo resistance of herpes simplex virus to 9-(2-hydroxymethyl) guanine (acycloguanosine). Antimicrob Agents Chemother. 1980;17:144-50. CrossrefMedlineGoogle Scholar30. DARBYFIELD GH. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. Nature. 1981;289:81-3. CrossrefMedlineGoogle Scholar31. COENSCHAFFER DP. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc Nat Acad Sci USA. 1980;77:2265-9. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Wayne State University School of Medicine Detroit, Michigan PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe varicella-zoster virus: Systemic and ocular featuresHerpes Simplex Chorioretinitis in a Healthy AdultThe Clinical use of Intravenous AcyclovirHERPETIC EYE DISEASEHerpes Zoster: An Approach to Systemic Therapy 1 March 1982Volume 96, Issue 3Page: 370-372KeywordsAllergy and immunologyBone marrow transplantationClinical trial reportingHerpes simplexInfectious diseasesNucleosides Issue Published: 1 March 1982 PDF downloadLoading ...